MedTrace Logo

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

NCT02301130 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-04-25

No results posted yet for this study

Summary

Mogamulizumab in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors

Conditions

Interventions

BIOLOGICAL

mogamulizumab

Mogamulizumab will be administered intravenously (IV).

BIOLOGICAL

MEDI4736 (Durvalumab)

MEDI4736 will be administered intravenously (IV).

BIOLOGICAL

tremelimumab

Tremelimumab will be administered intravenously (IV).

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Kyowa Kirin, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-26
Primary Completion
2017-12-08
Completion
2018-03-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02301130 on ClinicalTrials.gov